Pamela S. Espinoza-Loyola, Department of Surgery, Division of transplantation Surgery, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Luis J. Fernández-López, Department of Surgery, Division of transplantation Surgery, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Paul S. Mogrovejo-Vázquez, Department of Surgery, Division of transplantation Surgery, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Fernando Mondragón-Rodríguez, Department of Surgery, Division of transplantation Surgery, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
José A. González-Moreno, Department of Surgery, Division of transplantation Surgery, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Daniel A. Torres-Del Real, Department of Surgery, Division of transplantation Surgery, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Víctor M. Páez-Zayas, Departament of Gastroenterology, Division of Hepatology, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Carla A. Escorza-Molina, Departmanet of Anesthesiology, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Abril M. García-Sánchez, Department of Surgery, Division of transplantation Surgery, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Isidoro A. Sánchez-Cedillo, Department of Surgery, Division of transplantation Surgery, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Omar Vásquez-Gómez, Department of Surgery, Division of transplantation Surgery, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Óscar Chapa-Azuela, Department of surgery, Division of hepato-pancreato-biliary surgery. Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Víctor Visag-Castillo, Department of Surgery, Division of transplantation Surgery, Hospital General de México “Dr. Eduardo Liceaga,” Mexico City, Mexico
Pancreas transplant (PTx) is the only treatment that establishes normal glucose levels for patients diagnosed with diabetes types 1 and 2. The paper aims to review and analyze graft survival, patient survival, and the impact on diabetic complications. We describe that the graft survival was 82-98% at 1 year, 90% at 5 years, and 75-54% at 10 years for simultaneous pancreaskidney recipient; 71% pancreas after kidney (PAK), and 62% PTx alone at 1 year. Patient survival: At 1 year for recipients was 96.9% simultaneous pancreas-kidney transplantation (SPK); for PAK transplantation recipients, 96.3%; and for PTx alone recipients, 98.3%. In general, the pancreas transplantation improves and reverses diabetic complications. Finally, the pancreatic transplant is a morbid procedure and emerges as a significant alternative in diabetes management, directly competing with conventional insulin therapies. Results so far suggest that the most effective transplant model is the SPK. While more patients could benefit from this procedure, surgical complications and the need for immunosuppression pose significant challenges.
Keywords: Pancreas transplantation. Diabetes mellitus. Pancreas donor selection. Surgical technique. Outcomes.